BRIEF-Biogen says Opicinumab missed primary endpoint in study

* Says Reports Top Line results from phase 2 study of Opicinumab (anti-lingo-1) in multiple sclerosis
Data & News supplied by
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.